RDA Financial Network Increases Position in Vertex Pharmaceuticals Incorporated $VRTX

RDA Financial Network lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 17.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,419 shares of the pharmaceutical company’s stock after acquiring an additional 1,236 shares during the period. Vertex Pharmaceuticals accounts for approximately 0.9% of RDA Financial Network’s investment portfolio, making the stock its 27th biggest holding. RDA Financial Network’s holdings in Vertex Pharmaceuticals were worth $4,182,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in VRTX. Hilltop National Bank grew its stake in Vertex Pharmaceuticals by 11.4% during the 2nd quarter. Hilltop National Bank now owns 303 shares of the pharmaceutical company’s stock valued at $151,000 after purchasing an additional 31 shares during the last quarter. Western Wealth Management LLC lifted its holdings in shares of Vertex Pharmaceuticals by 159.7% during the first quarter. Western Wealth Management LLC now owns 1,631 shares of the pharmaceutical company’s stock worth $728,000 after purchasing an additional 1,003 shares during the period. Pacer Advisors Inc. boosted its position in Vertex Pharmaceuticals by 16.7% in the first quarter. Pacer Advisors Inc. now owns 88,863 shares of the pharmaceutical company’s stock valued at $39,681,000 after buying an additional 12,721 shares during the last quarter. First National Bank of Mount Dora Trust Investment Services boosted its position in Vertex Pharmaceuticals by 16.1% in the first quarter. First National Bank of Mount Dora Trust Investment Services now owns 7,211 shares of the pharmaceutical company’s stock valued at $3,220,000 after buying an additional 999 shares during the last quarter. Finally, Parallel Advisors LLC increased its holdings in Vertex Pharmaceuticals by 6.4% in the 1st quarter. Parallel Advisors LLC now owns 5,522 shares of the pharmaceutical company’s stock worth $2,466,000 after buying an additional 333 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $470.72 on Tuesday. The stock has a market capitalization of $119.47 billion, a price-to-earnings ratio of 27.92, a PEG ratio of 2.15 and a beta of 0.30. The firm’s 50 day simple moving average is $471.34 and its 200-day simple moving average is $460.44. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $533.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01). Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The firm had revenue of $3.33 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the prior year, the firm earned $4.52 earnings per share. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post 17.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the stock. UBS Group lifted their price objective on shares of Vertex Pharmaceuticals from $545.00 to $585.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Canaccord Genuity Group cut their price objective on shares of Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating on the stock in a research note on Tuesday, May 5th. Wall Street Zen cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, June 28th. Royal Bank Of Canada boosted their target price on shares of Vertex Pharmaceuticals from $543.00 to $570.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Finally, Weiss Ratings raised Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, July 17th. Twenty-two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $559.61.

Insider Buying and Selling

In other news, EVP Duncan Mckechnie sold 1,541 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total value of $799,779.00. Following the completion of the sale, the executive vice president directly owned 11,001 shares in the company, valued at $5,709,519. The trade was a 12.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 6,988 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $450.00, for a total value of $3,144,600.00. Following the transaction, the chief marketing officer directly owned 26,088 shares of the company’s stock, valued at approximately $11,739,600. The trade was a 21.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 17,452 shares of company stock valued at $8,103,997. 0.20% of the stock is owned by company insiders.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue rose 12.5% year over year to approximately $3.33 billion, exceeding Wall Street expectations. Growth was supported by continued demand for Vertex’s cystic fibrosis medicines, as well as contributions from sickle-cell disease, beta thalassemia and acute-pain treatments. Vertex Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Vertex raised its full-year 2026 revenue outlook to $13.1 billion-$13.2 billion, above the roughly $13.0 billion analyst consensus. The higher forecast reflects sustained strength in cystic fibrosis drug sales. Vertex raises annual revenue forecast
• Positive Sentiment: Profitability remained strong, with a 35.5% net margin and operating cash flow of approximately $1.4 billion. Vertex also highlighted strong growth from CASGEVY, its gene-edited therapy developed with CRISPR Therapeutics, and its expanding non-cystic-fibrosis pipeline.
• Neutral Sentiment: Vertex announced an agreement to acquire Crinetics Pharmaceuticals for approximately $10.0 billion in equity value, or about $8.8 billion net of estimated cash. The transaction would add PALSONIFY (paltusotine) and establish rare endocrine diseases as another major business area, but its scale may increase near-term execution and valuation risk. Crinetics acquisition announcement
• Negative Sentiment: Adjusted EPS was $4.73, narrowly below the $4.74 consensus; another data provider cited a $4.79 estimate. The modest miss likely drove the negative reaction despite revenue outperforming expectations and EPS increasing from $4.52 a year earlier. Vertex Pharmaceuticals Q2 Earnings Lag Estimates

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.